Abstract
Introduction
The cytotoxics market is mature and characterized by an increasing level of
genericization. Several blockbuster products will undergo patent expiry during
the forecast period, however, by virtue of these drugs' success, generic entry
will ensure continued growth. Coupled with the launch of several new brands,
steady growth of the cytotoxics market will occur to 2018, at a CAGR of 3.1%.
Scope of this research
- In-depth analysis of the current and future cytotoxic therapies market
across the US, 5EU and Japan, plus a rest of world snapshot
- Cytotoxic therapy sales forecasts for brands and generics from 2008 to 2018
- Assessment of the leading cancer brands and drug classes to identify key
success factors within this sector
- Assess the strategies of several leading players in the cytotoxics market
Research and analysis highlights
The cytotoxics market was worth $13.8 billion in 2008 across the seven major
pharmaceutical markets, and is forecast to grow to $18.7 billion by 2018,
achieving a CAGR of 3.1%. The launch of Dacogen (decitabine; Eisai/Johnson &
Johnson) and Vidaza (azacitidine; Celgene) in the 5EU and Japanese markets
will contribute significantly to this growth.
In 2008, Taxotere (docetaxel; Sanofi-Aventis), Eloxatin (oxaliplatin;
Sanofi-Aventis) and Gemzar (gemcitabine; Eli Lilly) were the top three
cytotoxics, with sales over $1 billion. Despite facing patent expiry during
the forecast period and guaranteed generic entry, Taxotere and Eloxatin will
remain in the top three in 2018, along with Dacogen.
The key events to impact the cytotoxics market during the forecast period are
the launch of new drugs, expansion into new indications and patent expiries.
Several blockbuster products with annual sales of over $1 billion are due to
undergo patent expiry during the forecast period, however, generic entry will
ensure continued market growth.
Key reasons to purchase this research
- Quantify the performance of each of the marketed cytotoxic therapy cancer
brands in the seven major markets over the period 2008 to 2018
- Acquire a detailed account of cytotoxic therapy cancer brand dynamics and
the events that drive and limit their market growth
- Benchmark the cytotoxic therapy cancer brands against their generics and
rest of class and align their 7MM performance with a rest of world snapshot
| 
View Cart
